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mixing. No thromboembolic complications occurred peri-
operatively or during 6 months follow-up. Prior to AF abla-
tion, incidence of LAA filling defects on double-contrast, 
single-phase CTA is low. TEE remains warranted in all but 
low-risk filling defects to rule out thrombus.
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Introduction
Catheter ablation (CA) is a frequently performed treatment 
in patients suffering from drug-refractory atrial fibrillation 
(AF). Prior to CA, exclusion of left atrial (LA) and left atrial 
appendage (LAA) thrombus is recommended as its presence 
is a contraindication for CA [1]. Al h ugh transesophageal 
echocardiography (TEE) is considered the gold standard 
for excluding LA and LAA thrombus [1, 2], it is a emi-
invasive procedure and associated with patient discomfort. 
Moreover, esophageal perforation is a very infrequent but 
potentially life-threatening complication [3–6]. Co se-
quently, different modalities, like computed tomography 
angiography (CTA), are increasingly used as a screening 
tool for LA/LAA thrombi.
On CTA, LAA filling defects may represent thrombus but 
also incomplete mixing of contrast and blood due to slow 
flow. In order to distinguish better between thrombus and 
slow flow, different delayed CTA imaging protocols have 
been developed. Previous studies showed 99 % specificity of 
a second delayed-phase CTA [7, 8]. Howev r, the extra radi-
ation exposure of a delayed scan remains a concern. There-
fore, in our daily clinical practice we use a single-phase, 
double-contrast injection protocol, with a delay between 
Abstract Prior to atrial fibrillation (AF) ablation, com-
puted tomography angiography (CTA) s increasing y used
for left atrial appendage (LAA) thrombus detection. LAA 
filling defects on CTA may represent thrombus or incom-
plete contrast mixing with blood. A pre-b lus of contrast 
material with delay before the CTA contrast bolus can help 
distinguish between thrombus and incomple e contrast 
mixing. We present results from a double-contrast, single-
phase CTA protocol used in our daily c inical practice. In 
patients who underwent AF ablation between 2011 and 
2015, double-contrast, single-phase CTA was performed 
prior to ablation. Two contrast boluses (30 and 70 ml) with 
25-s interbolus delay were administered followed by pro-
spectively triggered cardiac CTA. Only patients with left 
atrial (LA) or LAA filling defects underwent transesopha-
geal echocardiography (TEE) to rule out thrombus. Prior 
to ablation, 605 CTA-scans were erform d (median radia-
tion dose: 3.1 mSv). In 579 CTA-scans (95.7 %), the LA 
and LAA completely filled with contrast. In 26 CTA-scans 
(4.3 %) the LAA showed a filling defect whereby thrombus 
could not be excluded. In 2 of those 26 ati nts (7.7 % and 
0.3 % of the total population), TEE verified LAA thrombus. 
Low-risk LAA filling defects on CTA (n = 7/26) with an 
inhomogeneous aspect, Houndsfield Unit values >100, and 
an indefinite border were all caused by incomplete contrast 
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−300  mg I/ml, Bayer Schering Pharma AG, Berlin, Ger-
many] was administered followed by a delayed 70 ml con-
trast bolus, 25 s after the first administration of contrast, 
both at a flow rate of 6 ml/s. After the second contrast bolus, 
a 60 ml saline chaser (30 % contrast and 70 % s line) was 
administered, followed by 30 ml of saline. Contrast was 
adjusted to patient’s body weight (>80  kg: 35 an  80 ml,
respectively). The CTA-scan was initiated after the sec-
ond contrast bolus injection using a monitoring scan and a 
predefined threshold of 200 Hounsfield Units (HU) in the 
ascending aorta with a post-threshold delay of 7 s t  give 
breathing instructions. The scan parameters were as follows: 
collimation 128 × 0.625 mm, tube voltage 80–120 kV and 
tube current 195–210 mAs depending on weight (<65  kg, 
65–80 kg, >80  kg), and rotation time 0.27 s. Images were 
reconstructed with a slice thickness of 0.9 mm and a recon-
struction increment of 0.45 mm.
A filling defect was defined as an area of low attenuation 
in the LA or LAA, not caused by motion artifacts or other 
cardiac structures like atrial trabeculae. Houndsfield Units 
(HU) were measured throughout the area of low attenuation. 
Filling defects were classified as low, intermediate and high 
risk of thrombus based on the homogeneity of the region 
with low attenuation, HU-value and the border aspect. High 
risk filling defects consisted of homogeneous filling defects 
with low HU-values (<100  HU) [9 ] and a well-defined bor-
der (concave or convex). Low risk defects comprised inho-
mogeneous filling defects with high HU-values (>100  HU) 
and an ill-defined border. Filling defects were classified as 
intermediate risk of thrombus when both high and low risk 
characteristics were present.
Dose length products were registered during every exam-
ination. Radiation dose was calculated by the effective radi-
ation dose: (dose-length product) × (conversion fa or). The 
conversion factor varies for different body parts and for the 
heart it was set on 0.014 mSv/(mGy cm) [10].
Transesophageal echocardiography
In case of a LA or LAA filling defect, TEE (iE33, Philips 
Healthcare, Best, The Netherlands) was performed after a 
median of five (4–6) days after CTA. State of the art 5-MHz 
multiplane probes were used to visualize LA and LAA 
thrombi. Within the LAA, low-flow states were analyzed by 
pulsed-wave Doppler velocity interrogation and by identi-
fication of spontaneous echocardiographic contrast (SEC). 
Spontaneous echocardiographic contrast was characterized 
by dynamic echogenic swirling patterns of blood flow.
Anticoagulation strategy
Prior to CA, at least 4 weeks of adequate systemic anti-
coagulation with vitamin K antagonists (VKA) or novel 
the first and second bolus. A pre-contrast bolus with delay 
before the acquisition contrast injectio  may increase the 
diagnostic accuracy by better enhancement of he LAA.
In this study, we present results from a large cohort of 
patients from an academic hospital setting who underwent 
double-contrast, single-phase CTA prior to AF abl t on. 
All patients with LA or LAA filling defects on CTA under-
went TEE. Goals of this study are to (1) demonstrate the 
incidence of LAA filling defects on CTA in daily clinical 
practice, (2) show the positive pr dictive value for LAA 
thrombus detection of this approach and (3) analyze LAA 




Our Institutional Review Boa d approved this study, and 
based on the retrospective observational nature of this study 
waived the requirement to obtain written i forme  con-
sent. All consecutive patients suffering from symptomatic, 
drug-refractory or drug-intolerant AF who nderwent CTA 
prior to primary or redo catheter ablati n in the Univer-
sity Medical Center Utrecht from June 2011 to M y 2015 
were included. Transesophageal echocardiography was per-
formed to verify or rule out thrombus in all patients with any 
type of LA or LAA filling defect on CTA. Computed tomog-
raphy angiography and TEE were reviewed at the time f 
performance. In 2015, CTA and TEE we e r trospectively 
re-evaluated by a cardiovascular radiologist and a ca diolo-
gist, blinded for outcomes.
Patient characteristics were prospective y collected 
and comprised sex, age, AF type, history of AF (year  
since AF was diagnosed), cardiovascular risk factors, 
CHA 2DS2-VASc score, structural heart disease, LA size 
(end-systolic LA diameter in the parastern long axis view 
on echocardiography) and anticoagulation therapy. Atrial 
fibrillation type was classified as paroxysmal (PAF), per-
sistent or longstanding persistent according to  HRS/
EHRA/ECAS 2012 Consensus Statement o  Catheter and 
Surgical Ablation of AF [1].
Cardiac computed tomography angiogr phy
In all patients, double-contrast, single-pha e, p ospectively 
triggered cardiac CTA was perform d ≤7 days prior to t e 
ablation procedure to assess both LA and pulmonary vein 
(PV) anatomy, and exclude LA/LA  thrombus.
Computed tomography angiography was performed 
using a 256-slice CT system (Philips Healthcar , Cleveland, 
Ohio, USA). A 30 ml contrast bolus [Ultravist (iopromide) 
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CTA scans. In 579 CTA scans (95.7%), the LAA also com-
pletely filled with contrast (Fig. 1). In 26 CTA scans (4.3 %) 
the LAA showed a filling defect, whereby a thrombus could 
not be ruled out.
oral anticoagulants (NOAC) was required in all patients 
irrespectively of the CHA2DS2-VASc score. Patients with 
a CHA2DS2-VASc score ≥2 were preferably treated wi h 
VKA. In VKA, target values for the international normal-
ized ratio were 2.5–3.5. Vitamin K antagonists were contin-
ued peri-procedural. NOAC therapy was interrupted the day 
before CA and continued the day after.
During the ablation procedure, an intravenous bolus of 
heparin (≥5000  IU) was administered after trans-septal 
puncture, followed by additional boluses to maintain an 
activated clotting time between 300 and 350 s. After the 
ablation procedure, anticoagulation therapy was contin-
ued for at least 6 months. After 6 months, anticoagulation 
therapy was again individualized according to rhythm status 
and the CHA2DS2-VASc score.
Assessment of thromboembolic complications
After the ablation procedure, patients remained routinely 
hospitalized for one day. Patients were seen on the outpa-
tient clinic at 3 and 6 months after ablation. During hospital-
ization and at the outpatient clinic, occurrence of stroke and 
transient ischemic attack (TIA) was assessed. Stroke and 
TIA were defined according to the consensus report from the 
valve academic research consortium [11]. In s ort, diagnos-
tic criteria for TIA comprised new focal neurological deficit 
with symptoms resolution within 24 h, wi h ut rece t tissue 
injury on neuroimaging. Stroke was diagnosed if rapid onset 
of focal or global neurological deficit occurred, with a dura-
tion ≥24 h, and confirmed by a neurologist or neuroimaging 
[11].
Statistical analysis
Categorical patient variables were shown as number and 
percentages. Continuous variables were expressed as 
means ± standard deviation or as median (25th–75th per-
centile), depending on the normality of the data distribution. 
For the comparison of continuous variables, an independent 
t test or a Mann–Whitney U test was performed. Differences 
in categorical variables between groups were compared by 
the Chi square test. Positive predictive value (PPV) of CTA 
was calculated, using TEE as the gold standard. A p value 
<0.05 was considered statistical significant. Statistical anal-
yses were performed using SPSS 21.0 (IBM, Armonk, NY, 
USA).
Results
From June 2011 till May 2015, 477 patients underwent 605 
cardiac CTA scans prior to a total of 603 primary or redo CA 
procedures. No filling defects in the LA were seen in all 605 
Fig. 1 CTA showing complete filling of the LAA (yellow arrow), 
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LAA filling defects on CTA
In 26 patients, LAA thrombus could not be ruled out by CTA. 
During acquisition of CTA, 17 of these 26 (65.4 %) patien s 
were in AF. In 13 patients, the LAA filling defect had a 
homogeneous aspect with low HU values (<100) and a well-
defined border. Those patients were classified as high risk of 
thrombus by an experienced cardiovascular radiologists. The 
remaining 13 patients were classified as intermediate (n = 6) 
and low risk (n = 7) of thrombus. Both patients with LAA 
thrombus on TEE had a high risk filling defect on CTA. Com-
puted tomography angiography and TEE images of these two 
patients are shown in Fig. 2. No thromb  were found in the 
intermediate and low risk filling defect groups. Three exam-
ples of LAA filling defects (high, intermediate and low risk of 
thrombus) without thrombus on TEE are displayed in Fig. 3.
LAA thrombus on TEE
Of the 26 patients with LAA filling defects on CTA, 2 
patients showed LAA thrombus on TEE. Of the remaining 
24 patients, 6 patients showed severe SEC, 8 patients mod-
erate SEC and 8 patients no SEC. No TEE-associated com-
plications occurred.
Discussion
In this study we demonstrated that the incidence of LAA 
filling defects on double-contrast, single-phase CTA prior 
to AF ablation is very low. Yet, positive predictive value 
of CTA is low and TEE remains necessary to differentiate 
between thrombus and slow flow in case of LAA filling 
defects on CTA.
CTA vs. TEE
Computed tomography angiography is a multifunctional 
modality. Besides exclusion of LAA thrombus, it is pos-
sible to create a detailed three dimensional visualization 
of the LA, LAA and PV anatomy. This anatomy can be 
merged into electroanatomical maps of the ablation proce-
dure and may increase procedure efficacy. The use of only 
CTA, instead of both CTA and TEE, significantly reduces 
costs. Moreover, CTA is considered a patient friendly imag-
ing modality, while TEE is a semi-invasive procedure with 
patient discomfort, and has infrequent, but potentially life 
threatening complications.
CTA prior to AF ablation
The 2012 expert consensus statement on catheter ablation 
of AF states that CT imaging should not be used to screen 
Patients characteristics, divided into presence and 
absence of LAA filling defects on CTA, are shown in 
Table 1. Patients with LAA filling defects were more often 
female (57.7 % vs. 23.9 %, p < 0.001), suffered more from 
(longstanding) persistent AF (65.4 % vs. 45.2 %, p = 0.011)
and had a higher mean CHA2DS2-VASC  score (2.4 ± 1.7 vs. 
1.3 ± 1.3, p= 0.027).
Of the 26 patients with LAA filling defects on CTA, two 
showed LAA thrombus on TEE (PPV 7.7 %). In thes  two
female patients (0.3 % of the total population), AF was con-
tinuously present prior to CTA for 3 and 10 months respec-
tively. CHA2DS2-VASC  scores were two and three, and in 
both patients INR was between 2.5 and 3.5. Catheter ablation 
was postponed in these two patients. After 3 months of opti-
mal anticoagulation therapy, repeat d TEE show d re idual 
LAA thrombus in both patients and CA was cancelled.
In all 477 patients who underwent CA, no thromboem-
bolic complications occurred pe ioperatively and during 
6 months of follow-up. No major CTA related complica-
tions occurred (e.g. severe anaphylac ic reacti n to con-
trast or contrast-induced nephropathy). Five patients had a 
minor allergic reaction to contrast and all five made a full 
recovery. Median length product of all perform d CTAs was 
223 (138–230) mGy × cm, which corresponds to a median 
effective radiation dose of 3.1 (1.9–3.2) mSv.
Table 1 Baseline characteristics (n = 477)




Male sex 343 (76.1 %) 11 (42.3 %)†
Age at first ablation (years) 59.2 ± 10.3 52.2 ± 7.6
AF type
Paroxysmal 247 (54.8 %) 9 (34.6 %)‡
Persistent 178 (39.5 %) 12 (46.2 %)
Longstanding persistent26 (5.8 %) 5 (19.2 %)
History of AF (years)5.6 ± 5.6 6.2 ± 5.7
BMI (kg/m2) 27.1 ± 4.3 26  ± 4.1
Hypertension 174 (38.6 %) 8 (30.8 %)
Diabetes mellitus37 (8.2 %) 4 (15.4 %)
CHA 2DS2-VASc score1.3 ± 1.3 2.4 ± 1.7‡
Atrial flutter 122 (27.1 %) 7 (26.9 %)
Structural heart disease69 (15.1 %) 6 (23.1 %)
LA size (mm) 43 ± 7 46  ± 7
Anticoagulation
VKA 350 (77.6 %) 22 (84.6 %)
NOAC 101 (22.4 %) 4 (15.4 %)
Negative CTA no LAA filling defect present on CTA, Positive CTA 
LAA filling defect present on CTA, AF atrial fibrillation, BMI body 
mass index, CTA computed tomography angiography, LA left atrium, 
NOAC novel oral anticoagulants, VKA vit min K antagonist
†p value <0.01, ‡p value <0.05
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our understanding that complete filling of the LAA with 
contrast excludes thrombus. Therefore, we considered it 
safe and ethical to perform TEE only in case of LA or LAA 
filling defects on CTA. This is supported by the fact that no 
strokes or TIAs occurred perioperatively and up to 6 months 
after ablation. Nevertheless, silent cerebral thromboembolic 
lesions could not be ruled out, since no cerebral magnetic 
resonance imaging (MRI) was performed prior to and after 
ablation.
Recently, a novel clinical protocol was presented for 
safely integrating results of CTA delayed imaging of the 
LAA into pre-procedure care [8]. Based on this protocol, 
for LA/LAA thrombi and that TEE is r qu red. Prior to CA, 
TEE should be performed in all patients with AF more than 
48 h in duration [1].This recommendation is based on two 
studies (n = 499) that showed reduced sensitivity (29 and 
36  %) of CTA in LAA thrombi detec i n compared with 
TEE [12, 13]. Remarkably, a more rec nt meta-a alysis, 
which included all 19 relevant tudies (n =2955), including 
the previously mentioned low e sitiv ty studies, show d an 
overall sensitivity of 96 %. Sixteen the 19 included stud-
ies showed a sensitivity of 100 % [7]. Moreover, two studies 
using a similar double-contr st, s gle-phase CTA pro oc l
showed 100 % sensitivity [14, 15]. This is congruent with 
Fig. 2 Two patients with a LAA filling defect on CTA based on throm-
bus. a CTA in axial view showing a LAA filling defect (yellow arrow). 
The area of low attenuation shows a homogeneous aspect, HU 50–70 
and a well-defined concave border. b, cTEE showing a solid structure 
adherent to the LAA wall most likely thrombus (red arrow).d CTA 
in axial view showing LAA filling defect (yellow arrow). The area of 
low attenuation shows a homogeneous aspect, HU 70–90 and a well-
defined convex border. e TEE howing LAA thrombus (red arrow). f
Pulse -wave Doppler showing low LAA flow velocity
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images are obtained twice: immediately after contrast injec-
tion and with a 30–120 s delay after the contrast bolus. 
Earlier single-phase CTA studies showed a mean weighted 
sensitivity of 91 %, specificity of 95 %, PPV of 33 % and 
NPV of 100 % for LAA thrombus detection [7]. Recent 
studies using delayed-phase CTA demonstrated a sensitivity 
and NPV of 100 %, specificity of 99 % and PPVs ranging 
from 79 to 100 % [8, 6–19 ]. In case of LAA filling defects, 
delayed imaging seems more capable of differentiating 
between thrombus and slow flow [7]. However, a concern 
of delayed-phase imaging is the increased radiation dose of 
the double CTA scan.
Instead of a second delayed-phase CTA, a double-con-
trast, single-phase CTA scan (as used in our patients) can 
be performed by administering contrast twice with a delay 
between the first and second contrast bolus. The incidence 
TEE in addition to delayed-phase CTA was still necessary 
to exclude LAA thrombus in 24 % of patie ts. In contras , 
using our protocol, TEE was on y necessary in <5 % of 
patients.
Different CTA imaging protocols
Lack of atrial contractions in AF cause low atrial filling and 
emptying velocities, as compared with individuals in sinus 
rhythm. As a result, contrast opacification of the LAA might 
take longer. Therefore, different d layed imaging protocols 
have been developed to reduce the number of false posi-
tive CTAs. Left atrial appendage hrombi detection can be 
performed by using single-phase and de ayed-phase cardi c
CTA. In single-phase CTA, images are obtained im ed-
ately after contrast administratio . I delayed-phase CTA, 
Fig. 3 Three patients with false positive CTA scan. LAA filling 
defects were classified as high (a), intermediate (d) and low (g) risk 
of thrombus. The patients with a high and low risk filling defect were 
in AF during performance of CTA, the patient with an intermediate 
risk filling defect was in sinus rhythm. a CTA in axial view showing 
LAA filling defect (yellow arrow). The area of low attenuation shows 
a homogeneous aspect, HU 50–70 and a well-defined convex border. 
b TEE showing severe spontaneous echo contrast (red arrow) in the 
LAA without thrombus. c Low velocity measured by pulse Doppler. 
d CTA in axial view showing LAA filling defect (yellow arrow). The 
area of low attenuation shows a inhomogeneous aspect, HU 70–110 
and a well-defined convex border. e TEE showing no thrombus and no 
spontaneous echo contrast (red arrow). fH gh veloci y measured by 
pulse Doppler. g CTA in axial view showing LAA filling defect (yellow 
rrow). The area of low attenuation shows a inhomogeneous aspect, 
HU 150–250 and an ill-defined border. h TEE showing moderate spon-
taneous echo contrast in the LAA without thrombus (red arro).i Low 
velocity measur d by pulse Doppler
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retrospectively in all scans. More prospective studies are 
required to explore these novel acquisition techniques.
Limitations
First, this was a retrospective cohort study with limitations 
associated with this study design. The low incidence of LAA 
filling defects and PPV in our study could only be compared 
with studies from other institutions.
Second, TEE was only performed in patients with LAA 
filling defects on CTA. Because of this approach, negative 
predictive value, sensitivity and specificity of CTA could 
not be calculated.
Conclusion
Prior to AF ablation, incidence of LAA filling defects on 
double-contrast, single-phase CTA is low. TEE is still nec-
essary to differentiate between thrombus and slow flow in 
case of LAA filling defects on CTA with high risk character-
istics (homogeneous filling defects, low HU-values (<100 
HU) or a well-defined border). In patients with low risk 
LAA filling defects, TEE might not be warranted.
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